Warning letter
McKesson Corporation Headquarters 2/7/19: warning letter of Feb 7, 2019
FDA warning letter 565854 · Division of Pharmaceutical Quality Operations IV
Key facts
| Reference number | 565854 |
|---|---|
| Company | McKesson Corporation Headquarters 2/7/19 |
| Subject | McKesson Corporation Headquarters, Drug Product/Adulterated |
| Issue date | Feb 7, 2019 |
| Posted date | Feb 12, 2019 |
| Issuing office | Division of Pharmaceutical Quality Operations IV |
| Product type | Drugs |
| Inspection city | San Francisco |
| Inspection ZIP | 94104-5203 |
| Inspection start date | Jun 25, 2018 |
| Letter on fda.gov | fda.gov |
At a glance
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: